文献速递前列腺癌

前列腺健康指数指导大型队列活检决策的2年前瞻性评估

A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort.
PubMed 文献 · BJU Int · 2024-07-04

研究前瞻性纳入2016年5月至2017年8月香港16个公立泌尿科单位中PSA 4–10 ng/mL且直肠指检正常的男性,评估前列腺健康指数(PHI)对活检决策的影响。共2828例随访2年,82%患者PHI<35;知晓PHI后83%高PSA患者决定不活检,PHI≥35组初始ISUP GG≥2癌检出率23%高于<35组的7.9%。

要点

  • 知晓PHI结果后,83%的高PSA患者决定不接受前列腺活检。
  • PHI<35组与≥35组分别有11%和45%选择活检。
  • PHI≥35组初始ISUP GG≥2癌检出率23%,高于PHI<35组的7.9%。

核心结论

  • 在真实临床路径中纳入PHI后,83%的高PSA患者决定不接受前列腺活检。
  • PHI路径较PSA驱动策略提高了高级别前列腺癌检出率。
  • 较高的基线PHI可预测2年后的活检结果。
  • PHI可作为个体化活检决策和随访频率的工具。

研究设计与样本

  • 前瞻性评估2016年5月至2017年8月香港全部16个公立泌尿科单位中接受PHI检测的合格患者。
  • 纳入标准为PSA 4–10 ng/mL且直肠指检正常。
  • 所有患者接受PHI检测并向其解释结果及意义,随后与泌尿科医生通过共享决策制定随访计划。
  • 患者随访2年,分析活检率及活检结果与初始PHI测量的关系。

主要发现

  • 共2828例患者随访2年,82%的患者PHI结果处于较低风险范围(评分<35)。
  • 知晓PHI结果后,83%的高PSA患者决定不接受活检。
  • PHI评分<35组和≥35组分别有11%和45%选择活检。
  • 初始ISUP GG≥2癌检出率在PHI≥35组为23%,高于PHI<35组的7.9%。
  • 在初始活检无阳性发现的患者中,中位随访2.4年时后续ISUP GG≥2癌阳性活检率在PHI≥35组为34%,高于PHI<35组的13%。

临床怎么用

  • 在真实临床环境中将PHI纳入常规临床路径后,83%的高PSA患者决定不接受前列腺活检。
  • PHI路径较PSA驱动策略提高了高级别前列腺癌检出率。
  • 较高的基线PHI可预测2年后的活检结果。
  • PHI可作为个体化活检决策和随访频率的工具。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To prospectively evaluate how the Prostate Health Index (PHI) impacts on clinical decision in a real-life setting for men with a prostate-specific antigen (PSA) level between 4 and 10 ng/mL and normal digital rectal examination. PATIENTS AND METHODS: Since 2016, the PHI has been available at no cost to eligible men in all Hong Kong public hospitals. All eligible patients who received PHI testing in all public Urology units (n = 16) in Hong Kong between May 2016 and August 2017 were prospectively included and followed up. All included men had a PHI test, with its result and implications explained; the subsequent follow-up plan was then decided via shared decision-making with urologists. Patients were followed up for 2 years, with outcomes including prostate biopsy rates and biopsy findings analysed in relation to the initial PHI measurements. RESULTS: A total of 2828 patients were followed up for 2 years. The majority (82%) had PHI results in the lower risk range (score <35). Knowing the PHI findings, 83% of the patients with elevated PSA decided not to undergo biopsy. In all, 11% and 45% opted for biopsy in the PHI score <35 and ≥35 groups, respectively. The initial detection rate of International Society of Urological Pathology (ISUP) Grade Group (GG) ≥2 cancer was higher in the PHI score ≥35 group (23%) than in the PHI score <35 group (7.9%). Amongst patients with no initial positive biopsy findings, the subsequent positive biopsy rate for ISUP GG ≥2 cancer was higher in the PHI score ≥35 group (34%) than the PHI score <35 group (13%) with a median follow-up of 2.4 years. CONCLUSION: In a real-life setting, with the PHI incorporated into the routine clinical pathway, 83% of the patients with elevated PSA level decided not to undergo prostate biopsy. The PHI pathway also improved the high-grade prostate cancer detection rate when compared to PSA-driven strategies. Higher baseline PHI predicted subsequent biopsy outcome at 2 years. The PHI can serve as a tool to individualise biopsy decisions and frequency of follow-up visits.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Chiu PK, Liu AQ, Lau SY, et al. A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort. BJU Int. 2024. PMID: 38961793. doi:10.1111/bju.16457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。